Clinical characteristic and treatment of breast cancer patients with interstitial lung disease
Objective To analyze the clinical characteristics and treatment of breast cancer patients with interstitial lung disease(ILD).Method The medical records of 76 patients with breast cancer were collected to analyze their clini-cal characteristics,examination results,the use of antitumor drugs,the occurrence and treatment of ILD.Result Among 76 patients with breast cancer combined with ILD,9 patients had no obvious symptoms,and the other 67 patients had re-spiratory and other symptoms.CT examination showed different degrees of interstitial changes,and 52 patients showed different degrees of hypoxemia and respiratory failure.A total of 46 patients received systemic chemotherapy,27 patients of targeted drugs,2 patients of emettrastuzumab,and 1 patient of endocrine drug fulvestrant.The occurrence of ILD in taxanes was the highest,while in targeting drugs,the occurrence of ILD in everolimus was the highest,and the occur-rence of ILD in endocrine drugs was the lowest.According to common terminology criteria for adverse event(CT-CAE)classification,9 patients were grade 1,59 patients were grade 2,8 patients were grade 3.The ILD condition of all patients were significantly improved after treatment.Conclusion The anti-tumor drugs that cause ILD are mainly cyto-toxic drugs such as taxanes,gemcitabine cytotoxic drugs,and mechanistic target of rapamycin kinase(MTOR)inhibitor.To master the clinical characteristics and treatment methods of ILD patients,and select appropriate treatment plans for breast cancer patients with ILD can not only increase drug efficacy,but also reduce adverse drug reactions and improve the prognosis of patients.
breast cancerinterstitial lung diseaseclinical characteristictreatment
万方数据
维普
